Opinion|Videos|January 10, 2025
Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas
Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Several studies are evaluating the use of bispecific therapies in earlier lines of therapy for both diffuse large B-cell lymphoma and follicular lymphoma. What patient populations are most likely to benefit from bispecific therapies in earlier lines of therapy?
Advertisement
Related to this article
Systematic review finds combined immunonutrition (arginine, omega-3s, glutamine) in colorectal cancer surgery may cut surgical site infections, while single supplements show no benefit.
FACT Accreditation lets Tennessee Oncology bring community oncology CAR T-cell therapy closer to home, expanding access for non-Hodgkin lymphoma patients.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
3
Access and Innovation in North Carolina’s Research Triangle
4
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
5